The pioneering steps of KPS began with the development of the first IT equipment 20 years ago.

It was a stage used in the manufacturing process of semiconductors and displays,
requiring ultra-precise control over a wide range of processes in units of a nanometer,
which is one millionth of a millimeter.
With the distinct technological strengths as a stepping stone,
KPS has established its reputation in the industry as
a manufacturer of organic light emitting diode (OLED) process equipment for the past 10 years.

Recently, a new lineup of welding equipment and various inspection equipment was introduced,
which are instrumental for the entire process of manufacturing OLED panels.
KPS is also the supplier of the tensioning equipment for OLED masks and inspection equipment
to the first OLED mass production lines of Samsung Display and LG Display.

We are the world-first manufacturer of developing a system for OLED mass production.
Now, beyond its role as an important supplier of Samsung and LG,
the company is also a major partner of key brands in Chinese panel makers, BOE, CSOT, and TIANMA.

Mass production of real RGB OLED panels has been carried out only for smartphone displays.
However, the area shows signs of simultaneous and multi-faceted expansion to VR, tablet PCs, laptops, monitors, and TVs.
This is because global manufacturers such as
Apple, Samsung, LG, and BOE have entered into the fiercest competition for their shares in the OLED market.

KPS , a global top 3 manufacturers of OLED front-end process equipment,
is ready to dive into the ocean of global markets.
This is because the mass production of micro OLED, which is exclusively for VR/AR,
and the 8th-generation OLED panels for laptops and tablets, has entered the level of full implementation.
The mass production of OLED panels for TV is the next in line.

KPS has built a strong foundation of the company’s the internal structure and
systems of its main business including the revenue stream and structure,
and we now have another growth engine of a new business sector: a pharmaceutical and bio business.

Based on 30 years of experience in new drug development,
KPS established our subsidiaries ALGOK BIO Inc and BIXINK THERAPEUTICS.

The priority of these companies will be a fight against cancer, a long-standing challenge for humanity.

BIXINK, a domestic subsidiary, is responsible for the sale of anticancer agents that obtained marketing authorization and
also conducts research in the field of digital therapeutics,
an area drawing a growing attention as an alternative to offline therapy.
In particular, ALGOK BIO Inc, a US subsidiary, will assume the role of the BIO division of KPS with a pipeline of anticancer drugs.

KPS created an opportunity of synergistic combination between talented researchers and staff of two completely different fields,
IT and BT, both with extensive track record in R&D for decades, two years ago. This is fitting to the so-called metaverse era.

The convergence of IT and BT no longer remains as an attempt,
but is a natural course in this era.
From hardware devices that allow realization of VR to virtual hospitals
in which real treatment is possible,
the upcoming future of KPS is full of exciting promises.